GO
Loading...

Eli Lilly and Co

More

  • April 8- Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent. The growing market for atypical antipsychotics for schizophrenia was worth $4.5 billion in the United States, Pops said.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close. *Earnings season gets under way this week, with results due from companies including Alcoa Inc after the close, retailer Bed, Bath& Beyond on Wednesday, while financials JPMorgan Chase& Co and Wells Fargo& Co close out the week with results on Friday.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.

  • Early movers: NKE, TSLA, FB, NFLX & more Tuesday, 8 Apr 2014 | 7:51 AM ET
    Traders on the floor of the New York Stock Exchange react to an announcement from the Federal Reserve during the afternoon of March 19, 2014 in New York City. The Federal Reserve announced that it would cut bond purchases by $10 Billion.

    Some of the names on the move ahead of the open.

  • Eli Lilly ordered to pay $3B in diabetes drug case Tuesday, 8 Apr 2014 | 7:44 AM ET

    Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close. *Earnings season gets under way this week, with results due from companies including Alcoa Inc after the close, retailer Bed, Bath& Beyond on Wednesday, while financials JPMorgan Chase& Co and Wells Fargo& Co close out the week with results on Friday.

  • *Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. SAN FRANCISCO/ TOKYO, April 8- Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.

  • *Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. TOKYO, April 8- A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in damages over claims that it concealed cancer risks associated with its Actos diabetes drug, the plaintiffs' lawyer said on Tuesday.

  • April 8- A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug Actos were concealed, the plaintiffs' lawyer said. The jury in Lafayette, Louisana also order the payment of $1.475 million in compensatory damages in the suit.

  • April 6- Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The U.S. Food and Drug Administration has granted "breakthrough" status for palbociclib.

  • MannKind shares soar as diabetes drug gets nod Wednesday, 2 Apr 2014 | 8:10 AM ET
    MannKind's David Thomson

    U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.

  • Lightning Round: BlackBerry, Eli Lilly & More Tuesday, 1 Apr 2014 | 6:35 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Early movers: GM, UAL, JPM, LLY & more Tuesday, 1 Apr 2014 | 7:41 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • March 31- Eli Lilly was successful in a crucial legal battle on Monday when a U.S. The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the' 209 Patent are invalid.

  • March 31- Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.

  • March 24- Data storage provider Box Inc aims to raise about $250 million in an initial public offering, becoming the latest contender from a wave of "cloud-based" companies to test the frothy market for technology listings.

  • COPENHAGEN, March 20- Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.

  • March 12- The number of U.S. cattle deaths that may be linked to the Merck& Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.

  • March 12- The number of U.S. cattle deaths that may be linked to the Merck& Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.

Most Popular Video

Wednesday, 23 Apr 2014 | 10:50 PM ET

Taro Kono, Member of the House of Representatives in Japan's Parliament, says the Liberal Democratic Party (LDP) stands behind Prime Minister Shinzo Abe in pushing for the TPP trade deal.

Wednesday, 23 Apr 2014 | 10:34 PM ET

Charles Li, Chief Executive of Hong Kong Exchanges and Clearing, says the launch of a new commodity trading platform for three metal contracts will facilitate long-term cross-border investments.

Wednesday, 23 Apr 2014 | 10:16 PM ET

David Garrity, Principal at GVA Research, says Apple's decision to raise its dividend and step up its stock buyback program signaled confidence in the tech giant's outlook.